Fibronectin overexpression is associated with latentmembrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma

Li Jung Ma, Sung Wei Lee, Li Ching Lin, Tzu Ju Chen, I. Wei Chang, Han Ping Hsu, Kwang Yu Chang, Hsuan Ying Huang, Chien Feng Li

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Despite recent improvements in the diagnosis and treatment, the final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain suboptimal. Through data mining from published transcriptomic database with further bioinformatic validation, fibronectin (FN1) was identified as a differentially upregulated gene in NPC tissues, which implicates the transition from epithelial to mesenchymal phenotype (EMT) and promotes metastasis. Given the roles of fibronectin in risk stratification and in the frontline therapeutics of common carcinomas, such as renal cell cancer, we explored fibronectin immunoexpression status and its associations with clinicopathological variables and survival in a well-defined cohort of NPC patients. Fibronectin immunohistochemistry was retrospectively performed and analyzed using H-score for 124 biopsy specimens from NPC patients who received standard treatment without distant metastasis at initial diagnosis. Those cases with H-score higher than the median value were regarded as fibronectin overexpression. The findings were correlated with clinicopathological variables, EBV latent membrane protein 1 (LMP1) expression, disease-specific survival (DSS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Fibronectin overexpression was significantly associated with American Joint Committee on Cancer (AJCC) stages III-IV (p=0.019) and LMP1 expression (p=0.004), and univariately predictive of adverse outcomes for DSS, DMFS, and LRFS (all p<0.0001). In the multivariate comparison, fibronectin overexpression still remained prognostically independent to portend worse DSS (p<0.01, hazard ratio=5.958), DMFS (p<0.01, hazard ratio=5.728), and LRFS (p<0.01, hazard ratio=5.411) together with advanced AJCC stages III-IV. Fibronectin is upregulated in a subset of NPCs, and its increased immunoexpression significantly correlated with advanced features, justifying the potentiality of fibronectin as a theragnostic biomaker of NPC.

Original languageEnglish
Pages (from-to)1703-1712
Number of pages10
JournalTumor Biology
Volume35
Issue number2
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Fibronectins
Survival
Proteins
Neoplasm Metastasis
Recurrence
Membrane Proteins
Nasopharyngeal carcinoma
Epithelial-Mesenchymal Transition
Data Mining
Computational Biology
Human Herpesvirus 4
Renal Cell Carcinoma
Neoplasms
Immunohistochemistry
Databases
Carcinoma
Phenotype
Biopsy
Therapeutics

Keywords

  • Fibronectin
  • Nasopharyngeal carcinoma
  • Prognosis
  • Transcriptome

ASJC Scopus subject areas

  • Cancer Research

Cite this

Fibronectin overexpression is associated with latentmembrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma. / Ma, Li Jung; Lee, Sung Wei; Lin, Li Ching; Chen, Tzu Ju; Chang, I. Wei; Hsu, Han Ping; Chang, Kwang Yu; Huang, Hsuan Ying; Li, Chien Feng.

In: Tumor Biology, Vol. 35, No. 2, 01.01.2014, p. 1703-1712.

Research output: Contribution to journalArticle

Ma, Li Jung ; Lee, Sung Wei ; Lin, Li Ching ; Chen, Tzu Ju ; Chang, I. Wei ; Hsu, Han Ping ; Chang, Kwang Yu ; Huang, Hsuan Ying ; Li, Chien Feng. / Fibronectin overexpression is associated with latentmembrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma. In: Tumor Biology. 2014 ; Vol. 35, No. 2. pp. 1703-1712.
@article{0c6784dd594546b7b18a91fb75a4ac82,
title = "Fibronectin overexpression is associated with latentmembrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma",
abstract = "Despite recent improvements in the diagnosis and treatment, the final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain suboptimal. Through data mining from published transcriptomic database with further bioinformatic validation, fibronectin (FN1) was identified as a differentially upregulated gene in NPC tissues, which implicates the transition from epithelial to mesenchymal phenotype (EMT) and promotes metastasis. Given the roles of fibronectin in risk stratification and in the frontline therapeutics of common carcinomas, such as renal cell cancer, we explored fibronectin immunoexpression status and its associations with clinicopathological variables and survival in a well-defined cohort of NPC patients. Fibronectin immunohistochemistry was retrospectively performed and analyzed using H-score for 124 biopsy specimens from NPC patients who received standard treatment without distant metastasis at initial diagnosis. Those cases with H-score higher than the median value were regarded as fibronectin overexpression. The findings were correlated with clinicopathological variables, EBV latent membrane protein 1 (LMP1) expression, disease-specific survival (DSS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Fibronectin overexpression was significantly associated with American Joint Committee on Cancer (AJCC) stages III-IV (p=0.019) and LMP1 expression (p=0.004), and univariately predictive of adverse outcomes for DSS, DMFS, and LRFS (all p<0.0001). In the multivariate comparison, fibronectin overexpression still remained prognostically independent to portend worse DSS (p<0.01, hazard ratio=5.958), DMFS (p<0.01, hazard ratio=5.728), and LRFS (p<0.01, hazard ratio=5.411) together with advanced AJCC stages III-IV. Fibronectin is upregulated in a subset of NPCs, and its increased immunoexpression significantly correlated with advanced features, justifying the potentiality of fibronectin as a theragnostic biomaker of NPC.",
keywords = "Fibronectin, Nasopharyngeal carcinoma, Prognosis, Transcriptome",
author = "Ma, {Li Jung} and Lee, {Sung Wei} and Lin, {Li Ching} and Chen, {Tzu Ju} and Chang, {I. Wei} and Hsu, {Han Ping} and Chang, {Kwang Yu} and Huang, {Hsuan Ying} and Li, {Chien Feng}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s13277-013-1235-8",
language = "English",
volume = "35",
pages = "1703--1712",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Fibronectin overexpression is associated with latentmembrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma

AU - Ma, Li Jung

AU - Lee, Sung Wei

AU - Lin, Li Ching

AU - Chen, Tzu Ju

AU - Chang, I. Wei

AU - Hsu, Han Ping

AU - Chang, Kwang Yu

AU - Huang, Hsuan Ying

AU - Li, Chien Feng

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Despite recent improvements in the diagnosis and treatment, the final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain suboptimal. Through data mining from published transcriptomic database with further bioinformatic validation, fibronectin (FN1) was identified as a differentially upregulated gene in NPC tissues, which implicates the transition from epithelial to mesenchymal phenotype (EMT) and promotes metastasis. Given the roles of fibronectin in risk stratification and in the frontline therapeutics of common carcinomas, such as renal cell cancer, we explored fibronectin immunoexpression status and its associations with clinicopathological variables and survival in a well-defined cohort of NPC patients. Fibronectin immunohistochemistry was retrospectively performed and analyzed using H-score for 124 biopsy specimens from NPC patients who received standard treatment without distant metastasis at initial diagnosis. Those cases with H-score higher than the median value were regarded as fibronectin overexpression. The findings were correlated with clinicopathological variables, EBV latent membrane protein 1 (LMP1) expression, disease-specific survival (DSS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Fibronectin overexpression was significantly associated with American Joint Committee on Cancer (AJCC) stages III-IV (p=0.019) and LMP1 expression (p=0.004), and univariately predictive of adverse outcomes for DSS, DMFS, and LRFS (all p<0.0001). In the multivariate comparison, fibronectin overexpression still remained prognostically independent to portend worse DSS (p<0.01, hazard ratio=5.958), DMFS (p<0.01, hazard ratio=5.728), and LRFS (p<0.01, hazard ratio=5.411) together with advanced AJCC stages III-IV. Fibronectin is upregulated in a subset of NPCs, and its increased immunoexpression significantly correlated with advanced features, justifying the potentiality of fibronectin as a theragnostic biomaker of NPC.

AB - Despite recent improvements in the diagnosis and treatment, the final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain suboptimal. Through data mining from published transcriptomic database with further bioinformatic validation, fibronectin (FN1) was identified as a differentially upregulated gene in NPC tissues, which implicates the transition from epithelial to mesenchymal phenotype (EMT) and promotes metastasis. Given the roles of fibronectin in risk stratification and in the frontline therapeutics of common carcinomas, such as renal cell cancer, we explored fibronectin immunoexpression status and its associations with clinicopathological variables and survival in a well-defined cohort of NPC patients. Fibronectin immunohistochemistry was retrospectively performed and analyzed using H-score for 124 biopsy specimens from NPC patients who received standard treatment without distant metastasis at initial diagnosis. Those cases with H-score higher than the median value were regarded as fibronectin overexpression. The findings were correlated with clinicopathological variables, EBV latent membrane protein 1 (LMP1) expression, disease-specific survival (DSS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Fibronectin overexpression was significantly associated with American Joint Committee on Cancer (AJCC) stages III-IV (p=0.019) and LMP1 expression (p=0.004), and univariately predictive of adverse outcomes for DSS, DMFS, and LRFS (all p<0.0001). In the multivariate comparison, fibronectin overexpression still remained prognostically independent to portend worse DSS (p<0.01, hazard ratio=5.958), DMFS (p<0.01, hazard ratio=5.728), and LRFS (p<0.01, hazard ratio=5.411) together with advanced AJCC stages III-IV. Fibronectin is upregulated in a subset of NPCs, and its increased immunoexpression significantly correlated with advanced features, justifying the potentiality of fibronectin as a theragnostic biomaker of NPC.

KW - Fibronectin

KW - Nasopharyngeal carcinoma

KW - Prognosis

KW - Transcriptome

UR - http://www.scopus.com/inward/record.url?scp=84898887684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898887684&partnerID=8YFLogxK

U2 - 10.1007/s13277-013-1235-8

DO - 10.1007/s13277-013-1235-8

M3 - Article

C2 - 24081675

AN - SCOPUS:84898887684

VL - 35

SP - 1703

EP - 1712

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 2

ER -